Feedback / Questions
labetuzumab govitecan (IMMU-130) - Immunomedics
Immunomedics: Company Presentation
(Immunomedics)
-
Mar 20, 2016 -
Anticipated presentation of updated data from P2 trial (NCT01605318) in metastatic colorectal cancer in H1 2016
Anticipated P2 data
•
Colorectal Cancer • Oncology
http://www.immunomedics.com/pdfs/company-presentation.pdf
Mar 20, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious